154 results
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
-target side effects and safety issues associated with commercially available DHODH inhibitors. KIO-104 is formulated for intravitreal delivery
8-K
EX-99.1
s3lpvgb7aqb
12 Feb 24
Regulation FD Disclosure
5:23pm
8-K
EX-10.1
u1oidn1k
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
glgyfz9f84p
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.2
buwwaw f68yn
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
zmtcjjddqgb3e6ptfj5
9 Nov 23
Regulation FD Disclosure
7:02am
8-K
EX-99.1
cks70kh46 s4liofkf51
9 Nov 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
p4ed jip2u4unbj6wh
6 Nov 23
Topline Phase I/II First-in-Human Results Presented at AAO 2023
6:05am
8-K
EX-99.1
cfs514z
1 Aug 23
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
7:00am
8-K
EX-10.2
vgcwc o6b1
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-99.1
ih18va
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-1.1
vmtuys 3xm
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-99.1
qwgu8pcdh i8op
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-99.2
8vow 6wx3o
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm